What Is Sofosbuvir 400mg + Velpatasvir 100mg?

Sofosbuvir 400mg + Velpatasvir 100mg is a fixed-dose antiviral used to treat chronic hepatitis C infection. It combines two active ingredients in one once-daily tablet. Sofosbuvir is a nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase. Velpatasvir is a pan-genotypic inhibitor of the NS5A replication complex. Together they cover all six major hepatitis C genotypes. That means genotype testing is not needed before starting treatment in most cases.

How Does Sofosbuvir 400mg + Velpatasvir Work?

The two ingredients target separate stages of the hepatitis C replication cycle. Sofosbuvir blocks the NS5B RNA-dependent RNA polymerase. This enzyme is what the virus uses to copy its RNA. Without it, replication stops.

Sofosbuvir is absorbed and converted into a uridine nucleotide analogue inside the body. This form competes with the natural building blocks of viral RNA. Once it gets incorporated into the growing RNA chain, further copying is halted.

Velpatasvir works differently. It targets NS5A, a protein involved in RNA replication, viral assembly, and the formation of the membranous web where replication takes place. Blocking NS5A disrupts the process at several points at once. The two ingredients together produce a stronger antiviral effect than either would alone. Viral load typically becomes undetectable within a few weeks. Sustained virological response rates across genotypes 1 through 6 are consistently high.

What Conditions Does Sofosbuvir 400mg + Velpatasvir Treat?

The main approved use is chronic hepatitis C infection in adults and adolescents. It treats all six major genotypes without needing interferon or ribavirin in most patients. This is a big change from older treatment regimens. Treatment is typically 12 weeks for most genotype presentations.

Genotype 3 with cirrhosis or prior treatment failure may be handled differently in practice. The combination is also used in patients with compensated cirrhosis — liver scarring that has not yet progressed to liver failure. Results in this group are generally similar to non-cirrhotic patients. In decompensated cirrhosis, low-dose ribavirin is sometimes added, but that is a clinical decision. More detail on hepatitis C and its progression is available on the [hepatitis C condition page].

Sofosbuvir + Velpatasvir vs Other Direct-Acting Antiviral Combinations

Several other direct-acting antiviral combinations treat hepatitis C. Knowing how this one compares helps place it within the wider drug category.

Sofosbuvir + Ledipasvir covers genotypes 1, 4, 5, and 6. It is weaker against genotype 3. Ledipasvir is also an NS5A inhibitor but has a narrower genotypic range than velpatasvir. Sofosbuvir 400mg + velpatasvir 100mg covers genotype 3 more reliably. That matters in regions where genotype 3 is common.

By genotypic coverage, sofosbuvir 400mg + velpatasvir 100mg is the broadest single-tablet option currently available.

Available Forms: Brand Names and Generic Manufacturers

This combination comes in both originator and generic forms. The originator brand is Epclusa, made by Gilead Sciences. Generic versions are manufactured by [MANUFACTURER] and are bioequivalent to the originator.

GetHIV Treatment carries this combination for patients who order online. Each tablet contains sofosbuvir 400mg and velpatasvir 100mg in a single fixed-dose unit. Generic versions have opened up access in markets where originator pricing put treatment out of reach for most patients.

Store this medicine at controlled room temperature and keep it away from moisture. The tablet coating can degrade if exposed to humidity for extended periods — worth keeping in mind during transit in hot or humid climates.

Side Effect

Sofosbuvir 400mg + velpatasvir 100mg do not cause much side effects. Headache and fatigue are the most commonly reported effects. They occur in roughly 20 to 25 percent of patients in clinical trials. These are usually mild and tend to ease off as treatment continues.

Nausea is reported less often and is more common in the first two weeks. Gastrointestinal effects with this combination are generally less pronounced than with older interferon-based regimens.

Important Drug Interactions

Several drug classes interact with sofosbuvir 400mg + velpatasvir 100mg.

Rifampicin and other strong inducers of P-glycoprotein and CYP3A4 – these reduce plasma levels of both sofosbuvir and velpatasvir by speeding up their clearance. Rifampicin, carbamazepine, phenytoin, and St John’s Wort all fall into this group. Taking them together makes treatment ineffective.

HIV antiretroviral drugs – efavirenz reduces velpatasvir exposure significantly. This matters in patients being treated for both hepatitis C and HIV, where the full regimen needs to be considered together. Tenofovir alafenamide and emtricitabine do not significantly affect exposure to this combination.

Proton pump inhibitors – drugs like omeprazole lower velpatasvir plasma levels by changing gastric pH. How much this matters depends on the dose and timing.

A doctor should be consulted before taking this combination alongside other ongoing treatments.